Trans-Atlantic private equity healthcare specialist ArchiMed has sold health ingredients developer Fytexia to diversified food, ingredients and retail group, Associated British Foods, a FTSE 100 company.
Trans-Atlantic private equity healthcare specialist ArchiMed has sold health ingredients developer Fytexia to diversified food, ingredients and retail group, Associated British Foods, a FTSE 100 company.
The transaction – which sees Fytexia join the ABF Ingredients division – has earned ArchiMed’s inaugural MED I fund four times its investment. Following Fytexia’s sale, MED I retains its rank as the best performing buyout fund in the world across all sectors for the 2014 vintage, according to Preqin data.
MED I has returned four and a half times invested capital to limited partners to date. Its total return – including four realised and five remaining investments – is seven times invested capital.
Businesses previously sold by ArchiMed’s MED I include healthcare ingredients group HIS, for an annualised return of over 400 per cent; dental operator Primo, for three times investment; and gene and cell therapy technology specialist Polyplus-transfection for almost 70 times investment.
